UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 1725, 2010

GLOBAL MED TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)


Colorado	0-22083	84-1116894

(State or other jurisdiction of incorporation)	(Commission File No.)	(I.R.S. Employer Identification No.)


12600 West Colfax, Suite C-420, Lakewood, Colorado		80215

(Address of principal executive offices)		(Zip Code)

(303) 238-2000
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item 1.01.~~o ~~Entry~~Soliciting ~~into~~material apursuant ~~Material~~to ~~Definitive~~Rule ~~Agreement~~14a-12 under the Exchange Act (17 CFR 240. 14a-12)

Ono March 17, 2010, Global Med Technologies, Inc. (“Global Med” or the “Company”), Haemonetics Corporation, a Massachusetts corporation (“Haemonetics”), and Atlas Acquisition Corp., a Colorado corporation and a whollyPre-~~owned~~commencement ~~subsidiary~~communications of Haemonetics (the “Acquisition Sub”), executed Amendment No. 1 to the Agreement and Plan of Merger (“Amendment No. 1”), which amends the Agreement and Plan of Merger dated January 31, 2010 among Global Med, Haemonetics and Acquisition Sub (“Merger Agreement”) pursuant to ~~which,~~Rule ~~Acquisition Sub commenced a tender offer for shares of Global Med’s common stock, par value $0.01 per share~~ 14d-2(~~the “Global Med Common Stock”~~b), atunder ~~a price of $1.22 per share, net to~~ the ~~holders~~Exchange ofAct ~~Global Med Common Stock in cash, and for shares of Global Med’s Series A Convertible Preferred Stock, par value $0.01 per share~~ (~~“Global~~17 ~~Med~~CFR ~~Preferred Stock” and, together with Global Med Common Stock, the “Shares”), at a price of $1~~240.22 per share on a converted to common stock basis, net to the holders of Global Med Preferred Stock in cash (the “Offer”). Following the consummation of the Offer and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, the Acquisition Sub will merge into Global Med (the “Merger”) and Global Med shall continue as the surviving corporation. For further information on the Merger Agreement and the Offer, please see Global Med’s Current Report on Form 814d-~~K, filed on February~~ 2~~, 2010 with the Securities and Exchange Commission~~ (~~“SEC”~~b)~~, and the Merger Agreement filed as Exhibit 2.1 thereto.~~ )

~~Global~~o ~~Med,~~Pre-commencement ~~Acquisition~~communications ~~Sub~~pursuant ~~and Haemonetics have agreed~~ to ~~amend~~Rule ~~the~~13e-4(c) ~~Merger~~under ~~Agreement to reduce~~ the ~~termination~~Exchange ~~fee,~~Act ~~provided~~(17 ~~for~~CFR ~~in Section 9~~240.~~2 of the Merger Agreement, from $2.6 million to $2.~~13e-4 ~~million.~~ (c))

~~The description contained in this~~ Item 15.01 ~~of certain terms of the Amendment No~~. 1 ~~is qualified~~Changes in ~~its~~Control ~~entirety by reference to the full text~~ of ~~the Amendment No~~Registrant. ~~1, a copy of which is attached hereto as Exhibit 2.1 and incorporated herein by reference.~~

~~Item~~On January 831, 2010, Global Med Technologies, Inc. (“Global Med”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), which was subsequently amended on March 17, 2010, with Haemonetics Corporation, a Massachusetts corporation (“Haemonetics”), and Atlas Acquisition Corp., a Colorado corporation and a wholly-owned subsidiary of Haemonetics (the “Acquisition Sub”). Under the terms of the Merger Agreement, Acquisition Sub commenced a tender offer for shares of Global Med’s common stock, par value $0.01 per share (the “Global Med Common Stock”), at a price of $1.22 ~~Other~~per ~~Events~~share, net to the holders of Global Med Common Stock in cash, and for shares of Global Med’s Series A Convertible Preferred Stock, par value $0.01 per share (“Global Med Preferred Stock” and together with the Global Med Common Stock, the “Shares”), at a price of $1.22 per share on a converted to common stock basis, net to the holders of Global Med Preferred Stock in cash (the “Offer”).

OnAt ~~February 9,~~12:00 ~~2010~~midnight, ~~a shareholder of Global Med~~Boston, ~~Carmelo~~Massachusetts ~~J. Corica (“Plaintiff Corica”) filed a purported class action lawsuit (the “CJC Action”) against the Company~~time, ~~Acquisition~~on ~~Sub~~March 24, ~~Haemonetics,~~ ~~Michael I. Ruxin~~2010, ~~M.D.,~~the ~~Thomas~~Offer Fexpired. ~~Marcinek,~~As ~~Sarah~~of ~~L. Eames, T. Kendall Hunt and Robert~~the R.expiration ~~Gilmore~~of ~~(Dr. Ruxin,~~the ~~Mr. Marcinek~~Offer, ~~Ms. Eames~~3,960 ~~Mr. Hunt~~shares ~~and~~of ~~Mr. Gilmore,~~Global ~~collectively,~~Med ~~the “Individuals”~~Preferred Stock and ~~together~~approximately ~~with the Company~~31, ~~Acquisition Sub~~428, ~~and Haemonetics, the “Defendants”).~~730 ~~The~~shares ~~CJC~~of ~~Action alleges that the Individuals breached their fiduciary duties to~~ Global Med~~’s stockholders~~ ~~and~~Common ~~alleges~~Stock ~~that~~had ~~the~~been ~~sales~~tendered ~~process~~in ~~was~~and ~~neither~~not ~~honest~~withdrawn ~~nor~~from ~~fair, that~~ the ~~price~~Offer. ~~offered~~These istendered ~~inadequate,~~Shares ~~and~~constituted ~~that~~100% of the ~~Merger~~outstanding ~~Agreement~~shares ~~contains~~of ~~terms~~Global ~~that~~Med ~~discourage~~Preferred ~~other~~Stock ~~bidders~~ and ~~constrained~~approximately ~~Global~~82% ~~Med’s~~of ~~ability~~the tooutstanding ~~solicit~~shares ~~any~~of ~~other offers. The CJC Action also alleges that Haemonetics and~~ Global Med ~~aided~~Common ~~and abetted such alleged breach~~Stock. ~~Based~~Acquisition onSub ~~these allegations, the~~accepted ~~CJC~~for ~~Action~~payment ~~seeks~~all ~~judgment~~Shares ~~that,~~validly ~~among~~tendered ~~other relief: (1) provides injunctive relief that preliminarily~~ and ~~permanently~~not ~~enjoins~~properly ~~the~~withdrawn ~~Offer;~~in ~~(2) rescinds~~accordance ~~the~~with ~~Offer if it is consummated; (3) directs~~ the ~~Defendants~~terms ~~to account to Plaintiff Corica and other members~~ of ~~the class for all~~ ~~damages and any profits and other special benefits obtained by~~ the ~~Defendants~~Offer, asresulting in a ~~result~~change ~~of director~~in ~~defendants’~~control ~~breaches~~ of ~~their fiduciary duties; and (4) awards Plaintiff Corica the costs of the CJC Action, including the fees and expenses of Plaintiff Corica’s attorneys and experts.~~ Global Med ~~believes that the CJC Action is without merit~~.

OnIn ~~February 17~~addition, ~~2010,~~in aconnection ~~shareholder~~with the expiration of ~~Global~~the ~~Med~~Offer, ~~Joseph~~holders F.of ~~Sham~~warrants ~~(“Plaintiff~~exercisable ~~Sham”)~~to purchase an aggregate of 6,535,000 ~~filed~~shares aof Global Med Common Stock agreed that such warrants ~~purported~~would ~~class~~terminate ~~action~~immediately ~~lawsuit~~prior into the ~~District~~expiration ~~Court~~of ~~Jefferson~~the ~~County~~Offer, each in ~~Golden,~~exchange ~~Colorado~~for (the ~~“JFS~~right to ~~Action”),~~receive ~~against~~a ~~the~~lump ~~Defendants.~~sum ~~The~~cash ~~JFS~~payment ~~Action~~equal ~~purports~~ to bethe ~~brought~~product ~~individually~~of ~~and~~(i) the onexcess ~~behalf~~ of ~~all~~(A) the ~~holders~~per ofshare ~~Shares~~price for the Global Med Common Stock in the Offer over (~~other~~B) the ~~than~~per share exercise price for the applicable ~~Defendants~~warrant and (ii). the ~~The~~total ~~JFS~~number ~~Action~~of ~~alleges,~~shares ~~among~~of ~~other~~Global ~~things,~~Med Common Stock for which such ~~that~~warrant was then exercisable (the ~~Individuals~~“Cash ~~breached~~Out ~~their~~Payment”). ~~fiduciary~~On ~~duties~~March 26, 2010, the holder of a warrant exercisable to purchase 2,833,333 shares of Global Med’s ~~shareholders,~~Common Stock agreed that such warrant would be terminated immediately in exchange for the ~~bidding mechanism~~right ~~was~~to receive the Cash Out Payment with respect to such warrant.

~~-2-~~As a result of the foregoing, Parent became entitled under the Merger Agreement to designate three directors of Global Med, as described in more detail under Item 5.02 of this Current Report on Form 8-K below.

~~inadequate,~~Haemonetics ~~that~~and ~~the~~Acquisition ~~Individuals~~Sub ~~failed~~commenced toa ~~take~~subsequent ~~reasonable~~offering ~~steps~~period ~~to maximize the value realizable~~ for ~~the~~all ~~Shares,~~remaining ~~and that the price offered is unconscionable, unfair, and inadequate and~~untendered ~~constitutes~~shares ~~unfair~~of ~~dealing. The JFS Action also alleges that Acquisition Sub, Haemonetics and~~ Global Med ~~aided~~Common ~~and abetted such alleged breach~~Stock. ~~Based~~The onsubsequent ~~these~~offering ~~allegations,~~period ~~the~~will ~~JFS~~expire ~~Action~~at ~~seeks judgment that, among other relief~~12:00 ~~(1) provides injunctive relief against consummation of the~~midnight, ~~Merger~~Boston, ~~Agreement;~~Massachusetts ~~(2) awards~~time, ~~monetary~~on ~~and/or~~Wednesday, ~~rescissory damages; and (3)~~March ~~awards~~31, ~~Plaintiff Sham the costs of the JFS Action~~2010, ~~including~~unless ~~the fees and expenses of Plaintiff Sham’s attorneys and experts~~extended. ~~Global Med believes that the JFS Action is without merit.~~

~~Also~~Subject onto ~~February 17,~~the ~~2010,~~satisfaction aor ~~shareholder~~waiver of ~~Global~~the ~~Med,~~conditions ~~Robert~~set ~~O’Brien~~forth ~~(“Plaintiff~~in ~~O’Brien”), filed~~the aMerger ~~purported~~Agreement, ~~class action lawsuit in~~ the Acquisition ~~District~~Sub ~~Court~~will ~~Jefferson~~merge ~~County~~into inGlobal ~~Golden,~~Med ~~Colorado~~ (the “~~O’Brien Action~~Merger”), ~~against~~and ~~the~~Global ~~Defendants~~Med ~~and~~shall ~~Gerald~~continue ~~Willman,~~as the Jrsurviving corporation. ~~(an~~The ~~officer~~closing of ~~Global~~the ~~Med). The~~Merger ~~O’Brien~~is ~~Action~~subject ~~purports~~ to beapproval ~~brought~~by ~~individually and on behalf of all~~ holders of ~~Shares~~a ~~(other~~majority ~~than~~of the ~~Defendants~~then ~~and~~outstanding ~~Mr. Willman).~~shares ~~The O’Brien Action alleges, among other things, that the sale~~ of Global Med atCommon ~~the~~Stock ~~specified price is unfair~~ and ~~inadequate to~~ Global Med ~~shareholders,~~Preferred Stock. ~~that~~The ~~the~~parties, ~~Merger~~however, ~~Agreement~~have ~~contains~~agreed ~~terms~~ that ~~discourage~~in ~~other~~the ~~bidders~~event ~~from~~that ~~making~~Acquisition ~~successful competing~~Sub ~~offers,~~acquires ~~that~~at ~~certain~~least of90% of the ~~Individuals~~outstanding ~~were~~shares ~~motivated~~of toeach ~~secure~~of ~~personal~~Global ~~benefits, including~~Med ~~employment~~Common ~~agreements~~Stock and ~~change~~Global inMed ~~control~~Preferred ~~benefits,~~Stock ~~and that the Individuals breached~~(which ~~their~~shares ~~fiduciary~~of ~~duties~~Global inMed ~~approving~~Preferred ~~the~~Stock ~~Merger.~~have ~~The~~been ~~O’Brien~~acquired ~~Action~~by ~~also alleges that~~ Acquisition Sub, ~~Haemonetics~~pursuant ~~and~~to ~~Global~~the ~~Med~~Offer) then ~~aided~~outstanding ~~and~~on ~~abetted~~a ~~such~~fully ~~alleged~~diluted ~~breach.~~basis, ~~Based~~pursuant onto ~~these allegations,~~ the ~~O’Brien~~Offer ~~Action~~or ~~seeks judgment that~~otherwise, ~~among~~the ~~other~~parties ~~relief:~~shall take ~~(1) provides~~all ~~injunctive~~necessary ~~relief~~and ~~against consummating~~appropriate ~~the~~action ~~Merger;~~to ~~(2) directs~~cause the ~~Individuals~~Merger to ~~exercise~~become ~~their~~effective ~~fiduciary~~as ~~duties~~soon toas practicable ~~obtain~~without a ~~transaction~~ ~~providing~~meeting ~~the~~of ~~best~~shareholders ~~possible~~of ~~terms and consideration for~~ Global Med’s ~~shareholders;~~or ~~and (3) awards Plaintiff O’Brien~~ the ~~costs~~solicitation of ~~the~~written ~~O’Brien Action, including the fees~~ consents of ~~Plaintiff O’Brien’s~~such ~~attorneys~~shareholders, ~~and~~in ~~experts.~~accordance ~~Global~~with ~~Med~~applicable ~~believes that the O’Brien Action is without merit~~laws.

On March 9, 2010, Plaintiff Corica, Plaintiff Sham and Plaintiff O’Brien (together, the “Consolidated Plaintiffs”), having sought consolidation of the CJC Action, the JFS Action and the O’Brien Action pending in the District Court of Jefferson County in Golden, Colorado, jointly filed in each of these three lawsuits an amended class action complaint against the Defendants (the “Amended Complaint”). On March 10, 2010, the court entered an order consolidating the three actions. The consolidated action is captioned Carmelo J. Corica, Joseph F. Sham and Robert O’Brien v. Michael Ruxin et al., Case No. 10CV673. The Amended Complaint aggregates and restates the allegations and causes of action of the CJC Action, the JFS Action and the O’Brien Action. Additionally, the Consolidated Plaintiffs claim that the Individuals breached their fiduciary duties to Global Med’s shareholders by failing to make allegedly material disclosures to the shareholders in Global Med’s Schedule 14D-9 concerning additional details underlying the fairness opinion of St. Charles Capital, LLC delivered to Global Med and certain background information. Further, the Amended Complaint alleges that the Individuals approved the proposed transaction in order to provide liquidity to Global Med’s largest stockholder. Based on these allegations, the Amended Complaint seeks judgment that, among other relief: (1) provides injunctive relief that preliminarily and permanently enjoins the Offer; (2~~) rescinds the Offer if it is consummated; (3)~~ directs the Defendants to account to the Plaintiff and other members of the class for all damages and any profits and other special benefits allegedly obtained by the Defendants as a result of the Individuals’ alleged breaches of their fiduciary duties; and (4) awards the Consolidated Plaintiffs the costs of the action, including fees and expenses of the Consolidated Plaintiffs’ attorneys and experts. Global Med believes that the Amended Complaint is without merit.

OnAcquisition ~~March 10,~~Sub ~~2010,~~acquired the ~~Consolidated~~funds ~~Plaintiffs~~for ~~filed~~the apurchase ~~motion~~of ~~seeking~~the aShares ~~temporary~~tendered ~~restraining order~~in ~~to enjoin~~ the Offer. ~~The Consolidated Plaintiffs claim that (1) without a temporary~~from ~~restraining~~Haemonetics, ~~order~~which ~~there~~acquired ~~is a likelihood of irreparable harm to~~ the ~~Consolidated~~funds ~~Plaintiffs~~from ~~and~~its ~~no adequate~~available ~~remedy~~cash ~~at law, (2) the Consolidated Plaintffs have a substantial likelihood of success on the merits, (3) the threatened injury~~ resources.

~~-3-~~Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The Merger Agreement provides that, upon the payment by Acquisition Sub for Shares pursuant to the Offer, ~~Consolidated~~Acquisition ~~Plaintiffs~~Sub ~~and~~is ~~other~~entitled ~~shareholders~~to ~~outweighs~~designate ~~any~~a ~~possible~~number ~~harm~~of directors on the Board of Directors of Global Med as will give Acquisition Sub representation thereon equal to ~~Defendants~~at least that number of directors, rounded up to the next whole number, which is the product of (1) the total number of directors on the Global Med Board of Directors (giving effect to the directors elected pursuant to this sentence) multiplied by (2) the percentage that (i) such number of Shares so accepted for payment and paid for by Acquisition Sub plus the number of Shares otherwise owned by Haemonetics, Acquisition Sub or any other subsidiary of Haemonetics bears to (4ii) the ~~granting~~total number of Shares outstanding (on an as-converted basis with respect to the ~~injunction~~Global Med Preferred Stock without regard to any limitations on conversion), and Global Med would, at such time, cause Acquisition Sub’s designees to be so elected. The Merger Agreement further provides that Global Med will, ~~not~~upon Acquisition ~~disserve~~Sub’s request, use its best efforts either to increase the ~~public~~size ~~interest~~of the Board of Directors of Global Med or to secure the resignations of such number of Global Med’s incumbent directors as are necessary to effect this arrangement, provided that at all times prior to the Effective Time (as defined in the Merger Agreement), the Board of Directors of Global Med may include at least two persons who were members thereof prior to the Effective Time or other independent directors designated as such persons’ replacements. In addition, Global Med ~~believes~~further agreed that it would, if requested by Acquisition Sub, also take all action necessary to cause persons designated to the ~~motion~~Board ~~for~~of aDirectors ~~temporary~~of ~~restraining~~Global ~~order~~Med by Acquisition Sub to constitute at least the same percentage (rounded up to the next whole number) as is ~~without~~on ~~merit.~~the Board of Directors of Global Med of (1) each committee of the Board of Directors of Global Med, (2) each Board of Directors (or similar body) of each subsidiary of Global Med and (3) each committee (or similar body) of each such Board.

On March 1725, 2010, ~~the Consolidated Plaintiffs and the Defendants executed a Memorandum of Understanding~~ in ~~settlement of all claims and liabilities in the Amended Complaint (the “Settlement Memorandum”). In~~ connection with the ~~Settlement~~completion ~~Memorandum, Haemonetics has agreed to reduce the amount~~ of the ~~termination fee to $2.4 million. Global Med has agreed to amend the Schedule 14D-9 to include supplemental disclosure~~Offer, ~~without~~each ~~any admission to the materiality~~ of ~~such~~Robert ~~supplemental disclosures (those supplemental disclosures are all included in Amendment No~~R. 2 toGilmore, ~~the Schedule~~Sarah ~~14D-9)~~L. ~~The~~Eames ~~parties~~and ~~stipulated~~Thomas ~~that~~F. ~~the~~Marcinek ~~Offer~~resigned ~~shall~~as ~~remain~~directors ~~open for an additional five business days following the date~~ of ~~the~~Global ~~filing of Amendment No~~Med. 2 Pursuant to the ~~Schedule 14D-9~~Merger Agreement, ~~i.e.~~on March 2425, 2010., ~~The~~Brian ~~parties~~P. ~~have~~Concannon, ~~agreed~~Christopher ~~that confirmatory discovery shall be conducted involving depositions of a representative from St~~J. ~~Charles~~Lindop and ~~one~~Alicia ~~member of the Special Committee~~R. ~~The~~Lopez ~~parties have not~~were ~~reached~~appointed anas ~~agreement~~directors ~~concerning~~of ~~Consolidated~~Global ~~Plaintiffs’~~Med. ~~fees~~Messrs. Concannon and ~~costs,~~Lindop ~~if any,~~ and ~~the Defendants have not waived their right to challenge same on any grounds~~Ms. Lopez ~~Consolidated Plaintiffs will file~~are, ~~their application for fees and costs with the court at the appropriate time. The Settlement Memorandum is conditioned upon final approval by the court~~respectively, ~~along~~Parent’s ~~with~~Chief ~~customary~~Executive ~~provisions. If approved by the court~~Officer, ~~Defendants~~Chief ~~will~~Financial beOfficer ~~released by all class members described in the Amended Complaint (including the Consolidated Plaintiffs) from any claims~~ and ~~liabilities~~Vice ~~that~~President ~~were or~~of ~~could~~Business ~~have~~Development ~~been alleged in the Amended Complaint, including all actual or potential derivative, individual~~ and ~~class~~Vice ~~claims relating to the Offer~~President, ~~the~~Corporate ~~Merger~~Affairs. ~~Agreement, the Schedule~~Mr. ~~14D-9,~~Concannon ~~the Schedule TO,~~is oralso ~~any~~a ~~other~~member ~~disclosure or matter relating to or arising out~~ of ~~the Offer or Merger.~~ InParent’s ~~the~~Board ~~event~~of ~~the settlement is not finalized or finally approved by the court, we plan to vigorously defend against the Consolidated Plaintiffs’ claims~~Directors.

~~Item 9.01. Financial Statements and Exhibits.~~3

(d)		Exhibits.
		2.1				Amendment No. 1 to Agreement and Plan of Merger dated March 17, 2010 between Global Med Technologies, Inc., Haemonetics Corporation, and Atlas Acquisition Corp.

-4-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GLOBAL MED TECHNOLOGIES, INC. By: /s/ Michael I. Ruxin, M.D. Michael I. Ruxin, M.D. ~~Chairman and~~ Chief Executive Officer

Date: March 1829, 2010

~~-5-~~4

Exhibit Index

Exhibit No.		Description
2.1		Amendment No. 1 to Agreement and Plan of Merger dated March 17, 2010 between Global Med Technologies, Inc., Haemonetics Corporation, and Atlas Acquisition Corp.

-6-

Filing Compare · GLOBAL MED TECHNOLOGIES INC